Top Guns From Daiichi Sankyo Take Positions on Ranbaxy Board
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Japanese drug maker Daiichi Sankyo has reorganized the board of directors of Ranbaxy, a company in which it acquired 63.92 percent equity for an investment of $4.5 billion. Ranbaxy CEO and Managing Director Malvinder Mohan Singh will assume an additional role as chairman in the newly structured board
You may also be interested in...
As Daiichi Sankyo Takes Over Ranbaxy Reins, Japan’s Nippon Chemiphar May Exit Joint Venture
Ranbaxy owns half of Nippon Chemiphar subsidiary Nihon, with which it had planned to be influential in the Japanese generics market.
As Daiichi Sankyo Takes Over Ranbaxy Reins, Japan’s Nippon Chemiphar May Exit JV
MUMBAI - Ranbaxy and Nihon Pharmaceuticals, a subsidiary of Japan's Nippon Chemiphar, look set to end a joint venture they signed in 2002 to make an early entry into the Japanese generic market. That move is triggered due to a potential conflict of interest between Nippon Chemiphar and Ranbaxy's majority stakeholder Daiichi Sankyo in approaching the Japanese generic market
As Daiichi Sankyo Takes Over Ranbaxy Reins, Japan’s Nippon Chemiphar May Exit Joint Venture
Ranbaxy owns half of Nippon Chemiphar subsidiary Nihon, with which it had planned to be influential in the Japanese generics market.